Efficacy of Phycocyanin and Palmitoylethanolamide for the Treatment of Chronic Prostatitis Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-02

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a bothering condition characterized by pain localized to the pelvic, perineal and/or genital area and lower urinary tract symptoms (LUTS). Phytotherapy, which involves the combination of two or more active compounds, can be used to treat this challenging condition.

The aim of this study was to investigate the role of an association of phycocyanin (PC) and palmitoylethanolamide (PEA) and selenium (FICOXPEA®) in male patients affected by CP/CPPS.

The main questions the present study aims to answer are:

* Does FICOXPEA® enhance quality of life of CPP/CPPS patients?
* Does it help reducing pain symptoms of CPP/CPPS patients?

Researchers will investigate whether FICOXPEA® works to treat CPP/CPPS symptoms, so its efficacy, but also its tolerability and adherence to therapy.

Participants will:

* Take FICOXPEA® once a day for 30 days;
* Visit the clinic for follow-up visits at 1 and 3 months;
* Answer validated questionnaires and declare potential adverse events at follow-up visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Proxelan Somministration in Patients With Chronic Prostatitis

NCT03629769

Chronic Prostatitis Chronic Prostatitis With Chronic Pelvic Pain Syndrome Premature Ejaculation

UNKNOWN PHASE3

Treatment of Chronic Bacterial Prostatitis

NCT02130713

Chronic Bacterial Prostatitis

COMPLETED PHASE4

Bovine Colostrum Efficacy for the Treatment of Chronic Prostatitis Symptoms.

NCT06804083

Chronic Prostatitis (CP) Chronic Prostatitis With Chronic Pelvic Pain Syndrome Chronic Prostatitis/ Pelvic Pain Syndrome

COMPLETED PHASE4

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT03500159

Chronic Prostatitis Chronic Pelvic Pain Syndrome

TERMINATED PHASE2

Risk Factors for Chronic Prostatitis Patients in Northwest China

NCT06385977

Chronic Prostatitis With Chronic Pelvic Pain Syndrome

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Prostatitis (CP) Chronic Prostatitis With Chronic Pelvic Pain Syndrome Chronic Prostatitis/ Pelvic Pain Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

prospective, observational, multicentric, single-arm study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FICOXPEA®

FICOXPEA® is a phytoterapic compound made of:

* phycocyanin (spirulina platensis extract) 250 mg
* palmitoylethanolamide 200 mg
* L-selenometionine 11 mg

1. capsule containing all these compounds is administered every day for 30 days

Group Type EXPERIMENTAL

FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium

Intervention Type DRUG

FICOXPEA® is a phytoterapic compound made of:

* phycocyanin (spirulina platensis extract) 250 mg
* palmitoylethanolamide 200 mg
* L-selenometionine 11 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium

FICOXPEA® is a phytoterapic compound made of:

* phycocyanin (spirulina platensis extract) 250 mg
* palmitoylethanolamide 200 mg
* L-selenometionine 11 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult male patients (aged \>18 years)
* clinical affection by CP/CPPS with symptoms that persisted for ≥ 3 months;
* PSA values of 4 to 10 ng/ml (at least 2 determinations)
* patients must have completed diagnostic work-up, such as multiparametric prostate MRI (evidence level 1a according to EAU guidelines) with or without subsequent prostate biopsy (according to the diagnostic flow-chart depicted by EAU international guidelines).

Exclusion Criteria

* patients with previous diagnosis of prostate cancer
* patients who underwent previous low urinary tract surgery
* patients who underwent previous intravescical chemotherapy
* patients with acute bacterial prostatitis
* diagnostic work-up for prostate cancer not completed
* patients having antibiotic therapy or specific chronic prostatis treatment (phytotherapy included) or benign prostatic iperplasia treatment (e.g. alpha litics) at the time of the recruitment or finished less than a month before

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No